Clinical trial
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 76-week Study Evaluating the Safety and Efficacy of Two Doses of Simufilam in Subjects With Mild-to-Moderate Alzheimer's Disease
NCT05026177 is registered in ClinicalTrials.gov with Cassava Sciences, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 76-week Study Evaluating the Safety and Efficacy of Two Doses of Simufilam in Subjects With Mild-to-Moderate Alzheimer's Disease
- Lead sponsor
- Cassava Sciences, Inc.
- Phase
- Phase 3
- Overall status
- Terminated
- Start date
- November 18, 2021
- Completion date
- December 30, 2024
- Enrollment
- 1,125 (actual)
- Sites
- 89
Conditions
As the registry lists them; a condition with its own page is linked.